LLY | tickerfilter.com

Fundamental analysis

81%

Profitability 100%

Dept financing 33%

Liquidity 57%

Performance 80%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.83%

1 Month

-9.97%

3 Months

-1.68%

6 Months

-21.20%

1 Year

-2.45%

2 Year

95.45%

Key data

Stock price

$732.41

P/E Ratio

65.79

DAY RANGE

$711.98 - $735.84

EPS

$11.76

52 WEEK RANGE

$677.09 - $972.53

52 WEEK CHANGE

-$2.45

MARKET CAP

696.733 B

YIELD

0.67%

SHARES OUTSTANDING

950.426 M

DIVIDEND

$1.50

EX-DIVIDEND DATE

02-14-2025

NEXT EARNINGS DATE

05-01-2025

BETA

0.81

PUBLIC FLOAT

AVERAGE 10 VOLUME

$5,015,691

AVERAGE 30 VOLUME

$3,691,359

Company detail

CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

LLY - ELI LILLY & Co